IL-6, together with TGF-β, directly induces IL-17 production from pathogenic Th17 cells [19], and blocking of IL-6 has efficacy in RA treatment, in particular when anti-TNF treatment is inadequate [20]. The gene discussed is IL6; the disease is rheumatoid arthritis.